Entrada Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have jointly reported a 5.0% beneficial ownership stake in Entrada Therapeutics, Inc.
NASDAQ
T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 0.9% beneficial ownership stake in Entrada Therapeutics Inc.
NASDAQ
T. Rowe Price Associates, Inc. has disclosed a 6.8% beneficial ownership stake in Entrada Therapeutics Inc. common stock, held for passive investment purposes.
NASDAQ
Janus Henderson Group plc has filed an Amendment No. 2 to Schedule 13G, reporting a 4.0% beneficial ownership stake in Entrada Therapeutics, Inc. as of June 30, 2025.
NASDAQ
Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 5.6% in Entrada Therapeutics, Inc.'s common stock as of March 31, 2025.
NASDAQ
Roche Finance Ltd and its parent, Roche Holding Ltd, have reaffirmed their substantial passive ownership in Entrada Therapeutics, Inc., holding 6.9% of the common stock as of December 31, 2024.
NASDAQ
Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed beneficial ownership of 5.6% of Entrada Therapeutics, Inc.'s common stock as of December 31, 2024.
NASDAQ
BlackRock, Inc. has reported a beneficial ownership of 5.3% of Entrada Therapeutics, Inc.'s common stock as of December 31, 2024, in a routine Schedule 13G filing.